- Home
- ACXP vs IMRN Comparison
ACXP vs IMRN Comparison
Compare ACXP & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- IMRN
- Stock Information
- Founded
- ACXP 2017
- IMRN 1994
- Country
- ACXP United States
- IMRN Australia
- Employees
- ACXP N/A
- IMRN N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- IMRN Health Care
- Exchange
- ACXP Nasdaq
- IMRN Nasdaq
- Market Cap
- ACXP 8.4M
- IMRN 9.2M
- IPO Year
- ACXP 2021
- IMRN N/A
- Fundamental
- Price
- ACXP $0.31
- IMRN $1.65
- Analyst Decision
- ACXP Strong Buy
- IMRN Strong Buy
- Analyst Count
- ACXP 2
- IMRN 1
- Target Price
- ACXP $10.00
- IMRN $5.00
- AVG Volume (30 Days)
- ACXP 920.6K
- IMRN 665.1K
- Earning Date
- ACXP 08-12-2025
- IMRN 09-08-2025
- Dividend Yield
- ACXP N/A
- IMRN N/A
- EPS Growth
- ACXP N/A
- IMRN N/A
- EPS
- ACXP N/A
- IMRN N/A
- Revenue
- ACXP N/A
- IMRN $4,048,286.00
- Revenue This Year
- ACXP N/A
- IMRN N/A
- Revenue Next Year
- ACXP N/A
- IMRN N/A
- P/E Ratio
- ACXP N/A
- IMRN N/A
- Revenue Growth
- ACXP N/A
- IMRN 82.90
- 52 Week Low
- ACXP $0.29
- IMRN $1.50
- 52 Week High
- ACXP $2.39
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- ACXP 33.75
- IMRN 41.31
- Support Level
- ACXP $0.30
- IMRN $1.62
- Resistance Level
- ACXP $0.50
- IMRN $1.74
- Average True Range (ATR)
- ACXP 0.05
- IMRN 0.11
- MACD
- ACXP -0.02
- IMRN -0.01
- Stochastic Oscillator
- ACXP 7.86
- IMRN 20.94
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.